pharmaphorum

OCTOBER 31, 2022

Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing. The post Verge Genomics takes AI-sourced drug for ALS into clinic appeared first on. Alice Zhang.

Genome 134

Genome Genomics Drugs RNA 134

pharmaphorum

AUGUST 4, 2022

Unlocking the secrets of the human genome has long been an ambitious pursuit for researchers around the world. Today, the landscape of genomic testing and research is rapidly progressing, with significant scientific and technological advances driving a paradigm shift in the understanding of oncology at a molecular level.

Genome 52

Genome Genomics Genome Project DNA 52

Outsourcing Pharma

NOVEMBER 1, 2023

Element Biosciences, Inc., will share news of its sequencing methodology and host a workshop on higher accuracy sequencing for improved variant detection in Washington DC from today.

DNA 70

DNA Genome Genomics Regulation 70

BioTech 365

SEPTEMBER 21, 2020

DUBLIN–(BUSINESS WIRE)–The “DNA Sequencing – Technologies, Markets & Companies” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering. This report briefly reviews basics of human genome variations, development of sequencing technologies, and their applications.

DNA 40

DNA Marketing Genome Genomics 40

The Pharma Data

MARCH 7, 2022

Decision Regarding Slick-Haired Cattle is Agency’s First Enforcement Discretion Decision for an Intentional Genomic Alteration in an Animal for Food Use. IGAs are alterations made using molecular technologies that introduce changes to the genome of an animal. Today, the U.S. Solomon, D.V.M., Related Information.

Genome 52

Genome Genomics Production Marketing 52

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

The Pharma Data

JANUARY 31, 2021

NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Sequoia Capital China , a leading investment firm, today announced a collaboration to catalyze the startup ecosystem in China with the launch of the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.

Genome 52

Genome Genomics Life Science DNA 52

The Pharma Data

NOVEMBER 26, 2020

26, 2020 /PRNewswire/ — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link ‘ s AccuFind COVID-19 IgG antibody test in a healthcare setting. At present, most antibody tests on the market require samples to be sent to a lab for analysis.

DNA 52

DNA Antibody Research Genome 52

Pharmaceutical Technology

MARCH 28, 2023

The gene-editing technology allows for precise, directed changes to genomic DNA. It edits genes by precisely cutting DNA, then allowing natural DNA repair processes to take over. The system comprises the Cas9 enzyme and a guide RNA.

Gene Editing 235

Gene Editing DNA Gene Gene Therapy 235

STAT News

SEPTEMBER 1, 2022

SAN DIEGO — Sequencing behemoth Illumina on Thursday won its case against the Federal Trade Commission in its bid to hold onto Grail, a Bay Area early cancer detection company that the genomics giant acquired for $8 billion last year.

DNA 98

DNA Genome Genomics Marketing 98

XTalks

JUNE 16, 2023

XTALKS WEBINAR: Point-of-Care Diagnostics: Best Practices for Bringing Novel Solutions to Market Live and On-Demand: Thursday, July 13, 2023, at 1pm EDT (10am PDT) Register for this free webinar to gain insights from industry leaders on best practices for commercializing point-of-care diagnostic innovations. . billion in 2022 to $15.91

FDA Approval 97

FDA Approval Genome Genomics DNA 97

Drug Discovery World

FEBRUARY 6, 2024

Verge Genomics’ potential amyotrophic lateral sclerosis (ALS) treatment VRG50635 is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform 6. “For Automation is also being applied to genomics sample preparation, an area that requires particular robustness and scalability.

Marketing 69

Marketing Medicine Genome Genomics 69

Pharmaceutical Technology

JUNE 23, 2022

The increased infection rate of Covid-19 indicates the requirement for an alternative treatment development pipeline instead of the intensive process to launch new drugs to market, the researchers said.

Drugs 130

Drugs Protein Genome Genomics 130

pharmaphorum

OCTOBER 1, 2021

Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel its valuation up towards the £5 billion ($6.7 The post Oxford Nanopore makes stellar debut on UK stock market appeared first on. billion) mark.

Marketing 52

Marketing Business Development Genome Genomics 52

Drug Discovery World

MAY 25, 2023

DNA Script: SYNTAX DNA printing platform Using the company’s EDS technology, the SYNTAX platform can synthesise up to 96 highly accurate, ready-to-use DNA oligos with maximum lengths of up to 120nt in less than 24 hours in the laboratory. The platform works with the SYNTAX Hi-Fidelity reagent kits for synthesising longer oligos.

Production 52

Production Reagent DNA Drugs 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Genetics 130

Genetics DNA Antibody Genome 130

Pharmaceutical Technology

FEBRUARY 23, 2023

Moderna Genomics general manager and chief scientific officer Eric Huang said: “Through our collaboration with Life Edit, we hope to harness the power of gene editing technologies as part of our broader research and development engine, helping to advance our mission and deliver on the promise of mRNA.”

Gene Editing 147

Gene Editing Gene In-Vivo Gene Therapy 147

Roots Analysis

FEBRUARY 23, 2022

Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies. NGS Library Preparation Kits Market. Currently, close to 60 industry players are actively offering NGS kits for preparing DNA / RNA libraries.

Genetics 52

Genetics DNA RNA Reagent 52

pharmaphorum

OCTOBER 28, 2020

Stocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK start-up Base Genomics. billion, positioning it as a leader in the cancer-screening market. The company also announced the acquisition of Base Genomics, a UK epigenetics start-up for $410m.

Genome 64

Genome Genomics DNA Branding 64

pharmaphorum

OCTOBER 12, 2022

AstraZeneca has teamed up with DNA sequencing giant Illumina on a new programme that will use artificial intelligence to find new targets for drug discovery by sifting through vast arrays of data generated from “omics” studies.

Genome 64

Genome Genomics DNA Drugs 64

Drug Discovery World

FEBRUARY 21, 2023

Kristina Tatiossian , PhD, founder of Arkitekt Agency, looks at how biotech companies are currently using social media and provides a five-step guide for how to make the most of this ubiquitous marketing tool. Furthermore, marketing teams can tailor the organisation’s following to feature specific demographics.

Marketing 52

Marketing Branding Gene Therapy DNA 52

pharmaphorum

JANUARY 29, 2021

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, which are proteins that can be used to edit genomes by knocking select genes in or out to specifically modify DNA sequences.

Gene Editing 144

Gene Editing Gene Gene Therapy In-Vivo 144

The Pharma Data

JANUARY 31, 2021

Illumina , the world’s leading DNA sequencing and array-based technologies company, is partnering with Sequoia Capital China, an investment firm, to launch a life sciences incubator in China. It is dubbed the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.

Life Science 52

Life Science Genome Genomics Reagent 52

Drug Discovery World

MAY 16, 2023

The company’s DNA-based platform is being developed to address manufacturing challenges associated with the production of recombinant adeno-associated virus (rAAV) vectors used to produce advanced therapy medicinal products (ATMPs).

Production 52

Production Gene Therapy Gene Bioinformatics 52

Drug Discovery World

JUNE 5, 2023

The panel was moderated by Alexander Nuyken, Head Life Sciences Markets Europe, Middle East & Africa, JLL. I consider one of my responsibilities to advocate the advent of a new era for 3D genomics. Our final goal is to pioneer the 3D genomic field and demonstrate the impact on precision medicine.

Genome 52

Genome Genomics Life Science Genetics 52

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. Cell culture challenges The viral vectors used in the gene therapies currently on the market are produced in adherent human embryonic HEK-293 cell culture. The established method for this process is a triple transfection using three different DNA plasmids.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Drug Discovery World

FEBRUARY 8, 2024

This all creates numerous challenges for the market. These include automated solutions, proprietary genomics protocols, specialists to advise on global cGMP repository and logistics, plus experts to guide researchers through advanced therapy development. Dr O’Hara also provided an AAV plasmid preparation case study.

Gene Therapy 59

Gene Therapy Gene Bioinformatics Life Science 59

The Pharma Data

JANUARY 5, 2021

Genomic surveillance is essential in fighting the pandemic. Illumina is pleased to partner with the CDC and Helix to provide accurate sequencing that can contribute to rapidly scaling genomic surveillance in the US to better understand the presence of B.1.1.7 Illumina is improving human health by unlocking the power of the genome.

Genome 52

Genome Genomics Life Science Development 52

Drug Discovery World

FEBRUARY 13, 2023

How can technology help drug discovery research get to market faster and at optimum efficiency? Using AI, researchers at Chalmers University of Technology, Sweden succeeded in designing synthetic DNA that controls the cells’ protein production. What areas of technology will be key in helping maintain this innovation momentum?

Genome 52

Genome Genomics Life Science Drugs 52

Drug Discovery World

DECEMBER 21, 2023

Three trends in the antibody-drug conjugate (ADC) market Antibody-drug conjugates are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker. DDW Multimedia Editor Megan Thomas explored three trends in the market.

Gene Therapy 59

Gene Therapy Gene Antibody FDA Approval 59

XTalks

JULY 19, 2021

Phosphorus, a leading preventative genomics company, has developed the first comprehensive preventative genetic test for consumers. Like other consumer genomic tests, the Phosphorus GeneCompass test also involves the collection of saliva samples that consumers send to the Phosphorus lab located in Secaucus, NJ for analysis.

Genetics 98

Genetics Genome Genomics Gene 98

Pharmaceutical Technology

MARCH 9, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Regeneron Pharmaceuticals is the leading patent filer in transgenic murine models.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

The Pharma Data

DECEMBER 14, 2020

The global GBM treatment market is projected to reach $3.3 representing the largest market. engine along with algorithms tuned to predict BBB permeability played an important role in helping determine which CNS cancers and which genomically-defined subtypes of CNS cancer should be prioritized for development. .

Drugs 52

Drugs Genome Genomics DNA 52

Drug Discovery World

OCTOBER 3, 2023

This all creates numerous challenges for the market. These include automated solutions, proprietary genomics protocols, specialists to advise on global cGMP repository and logistics, plus experts to guide researchers through advanced therapy development. Dr O’Hara also provided an AAV plasmid preparation case study.

Gene Therapy 52

Gene Therapy Gene Life Science Bioinformatics 52

Drug Discovery World

SEPTEMBER 7, 2022

Olaparib, which was initially developed to treat women with ovarian and breast cancer, is part of a family of drugs called PARP inhibitors that target and kill cancer cells with faulty DNA repair machinery. The approval grants marketing authorisation for the use of olaparib in the UK. Biomarker testing “should be routine”.

Genetics 52

Genetics Drugs DNA Gene 52

The Pharma Data

DECEMBER 22, 2020

“We are truly excited and humbled to bring the power of diagnostic microarray testing to the Japanese market. NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. About Agilent Technologies. Agilent Technologies Inc.

Genome 40

Genome Genomics Genetics In-Vitro 40

The Pharma Data

SEPTEMBER 11, 2021

By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.

Antibody 52

Antibody DNA Containment Manufacturing 52